What is orforglipron?
Orforglipron is a GLP-1 receptor agonist developed by Eli Lilly. What sets it apart from most compounds in the same class is its structure: it is a small molecule, not a peptide. Semaglutide, tirzepatide and retatrutide are chains of amino acids that are broken down in the gut, which is why most of them are made as injections. Orforglipron was designed from the start as a non-peptide compound that can be taken by mouth as a pill, which changes what an orforglipron dosage question even means.
That design is why people search for orforglipron dosage, orforglipron pill and orforglipron bac water in the same breath. Anyone used to peptide vials expects a powder to mix. Orforglipron does not work that way: the product is a finished tablet with its strength fixed by the manufacturer. This page explains the product form and the related numbers. It makes no claims about effects in people.
Can you mix orforglipron with BAC water?
No, and there is no reason to try. Bacteriostatic water is used to reconstitute lyophilized (freeze-dried) injectable powders, such as research vials of semaglutide or tirzepatide. Orforglipron is an oral small molecule. The orforglipron pill is a finished solid product, and nothing about it is meant to be dissolved and drawn into a syringe.
With no vial mg and no water volume, there is no concentration to calculate and no U-100 syringe-unit math. That is why the calculator on this page is greyed out. If a listing offers orforglipron as a powder in a vial with a suggestion to add BAC water, that product is not the orforglipron tablet, and the label is the only information you have about what it contains. For the background on what bacteriostatic water is for, see what BAC water is.
Orforglipron dosage: what this page can and can’t tell you
Every page here follows the same rule: we do arithmetic on an amount you already have and never set, suggest or check one. For injectable peptides that arithmetic turns mg into syringe units. For orforglipron dosage there is no conversion step, because the strength of each tablet is printed on the product.
This page will not give an orforglipron dosage, a starting amount, a titration, a schedule or a frequency. Titration steps from clinical trials are dosing information, and we do not reproduce them. Those questions belong with the product labeling and a qualified professional. What we can do is explain how tablet strength is written.
Reading an orforglipron pill label
Tablet products state strength as mg per tablet. That figure refers to one tablet; the pack total is that number times the tablet count. Some listings also give strengths in mcg, so keep one unit fact in mind: 1 mg = 1,000 mcg.
- Per tablet, not per pack: the headline number on a box is almost always the strength of one tablet.
- Different strengths look alike: tablets of different strengths can share the same name, so read the mg figure on every pack rather than relying on the name.
- No syringe units: “units” on a U-100 syringe measure volume of liquid. They have no meaning for a tablet.
Orforglipron vs semaglutide
The most common comparison is orforglipron vs semaglutide. Both act on the GLP-1 receptor, but they are very different molecules. Semaglutide is a modified peptide. It is FDA-approved as injections (Ozempic and Wegovy) and as a tablet (Rybelsus), and research-labeled semaglutide is sold as freeze-dried vials that are reconstituted with BAC water. Orforglipron is a non-peptide small molecule made to be swallowed.
For this site the practical difference is the math. A semaglutide vial page reports micrograms per syringe unit after mixing, and its calculator converts an amount you already have into mL and units. An orforglipron tablet has a fixed mg strength and nothing to convert. The two numbers are not interchangeable, and one cannot be entered into the other’s calculator. We do not compare the two for effectiveness or safety.
Orforglipron regulatory status
Orforglipron is FDA-approved. Eli Lilly’s once-daily orforglipron tablet was approved in April 2026 under the brand name Foundayo for chronic weight management in adults, alongside diet and physical activity. That approval covers Lilly’s tablet only. Products sold online as “research” orforglipron are not Foundayo and are not approved medicine; their labels are the only information about what they contain.
Because it is an oral small molecule, orforglipron sits outside the reconstitution tools on this site. For compounds that are sold as freeze-dried vials and do need BAC water math, including other GLP-1 compounds, browse the peptide library, where each page has a mixing chart and a preselected calculator.
Orforglipron FAQ
Can you mix orforglipron with BAC water?
No. Orforglipron is an oral small-molecule tablet, not a freeze-dried injectable vial. There is nothing to reconstitute, so BAC water and syringe-unit math do not apply.
Is orforglipron a peptide?
No. Unlike semaglutide and tirzepatide, orforglipron is a small non-peptide molecule. That is what allows it to be made as a pill.
Does this page give an orforglipron dosage?
No. This site does not set or suggest amounts, titrations or schedules. The strength per tablet is on the label, and dosing questions belong with a qualified professional.
What is the difference between orforglipron and semaglutide?
Both act on the GLP-1 receptor. Semaglutide is a modified peptide sold as injections and a tablet, while orforglipron is a small molecule designed as a pill. This page compares their form, not their effects.
Is orforglipron FDA-approved?
Yes. Eli Lilly’s orforglipron tablet was FDA-approved in April 2026 as Foundayo. Research-labeled orforglipron sold online is not Foundayo and is not approved medicine.